Welcome to our dedicated page for Outset Medical news (Ticker: $OM), a resource for investors and traders seeking the latest updates and insights on Outset Medical stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Outset Medical's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Outset Medical's position in the market.
Outset Medical, Inc. reported its financial results for the first quarter of 2024, highlighting revenue of $28.2 million, a 12% growth in service and other revenue, and a total gross margin improvement to 29.2%. Operating expenses decreased by 10% from the prior year. The company remains focused on reducing costs, achieving profitability, and capitalizing on the $11 billion U.S. dialysis market opportunity.
Outset Medical, Inc. (Nasdaq: OM) received FDA 510(k) clearance for TabloCart with prefiltration, an accessory for the Tablo Hemodialysis System, improving flexibility for healthcare providers. This innovative technology enhances user experience with versatile prefiltration options and enhanced maneuverability, simplifying dialysis treatment. TabloCart complements Tablo as a single enterprise solution, revolutionizing the dialysis experience for patients and providers.
Outset Medical, a medical technology company (OM), will be presenting at upcoming investor conferences hosted by BofA Securities and RBC Capital Markets in May 2024. The management will discuss the company's innovative dialysis technology to reduce costs and complexity. Webcasts of the sessions will be available on Outset's investor section website.